• 1
    Doroshow JH. Anthracyclines and anthracenediones. In: Chabner BA, Long DL, eds. Cancer Chemotherapy and Biotherapy Principles and Practice. Philadelphia, PA: Lippincott-Raven; 1996: 409-434.
  • 2
    Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19: 670-686.
  • 3
    Hewitt M, Weiner SL, Simone JV, eds. Childhood Cancer Survivorship: Improving Care and Quality of Life. Washington, DC: National Academies Press; 2003.
  • 4
    Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 2009; 53: 2231-2247.
  • 5
    Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815.
  • 6
    Green DM, Hyland A, Chung CS, Zevon MA, Hall BC. Cancer and cardiac mortality among 15 year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol 1999; 17: 3207-3215.
  • 7
    Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in 5 year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001; 19: 3163-3172.
  • 8
    Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5 year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2328-2338.
  • 9
    Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 2629-2636.
  • 10
    Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer—a report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev 2010; 19: 170-181.
  • 11
    Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011; 117: 1806-1816.
  • 12
    Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort [serial online]. BMJ 2009; 339: b4606.
  • 13
    Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-1743.
  • 14
    Miller TL, Lipsitz SR, Lopez-Mitnik G, et al. Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 2010; 19: 2013-2022.
  • 15
    Rathe M, Carlsen NLT, Oxhoj H, Nielsen G. Long term cardiac follow up of children treated with anthracycline doses of 300 mg/m2 or less for acute lympoblatic leukemia. Pediatr Blood Cancer 2010; 54: 444-448.
  • 16
    Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 545-550.
  • 17
    Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28: 1308-1315.
  • 18
    Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics 1992; 89: 942-949.
  • 19
    Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 15: 4979-4990.
  • 20
    Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007; 25: 3635-3643.
  • 21
    Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Childrens Oncology Group [serial online]. Pediatrics 2008; 121: e387-e396.
  • 22
    Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother 2008; 42: 99-104.
  • 23
    van Dalen EC, van den Brug M, Caron HN, Kremer LC. Anthracycline induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer 2006; 42: 3199-3205.
  • 24
    Abosoudah I, Greenberg ML, Ness KK, Benson L, Nathan PC. Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors. Pediatr Blood Cancer 2011; 57: 467-472.
  • 25
    Children's Oncology Group Long-Term Follow-Up Guidelines Core Committee. Children's Oncology Group Long-Term Follow-Up (LTFU) Guidelines, Version 3.0. Bethesda, MD: Children's Oncology Group; 2008. Available at: Accessed on April 20, 2011.
  • 26
    Avelar T, Pauliks LB, Freiberg AS. Clinical impact of the baseline echocardiogram in children with high risk acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 57: 227-230.
  • 27
    Porea TJ, Dreyer ZE, Bricker JT, Mahoney DH Jr. Evaluation of left ventricular function in asymptomatic children about to undergo anthracycline-based chemotherapy for acute leukemia: an outcome study. J Pediatr Hematol Oncol 2001; 23: 420-423.
  • 28
    Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57: 2263-2270.
  • 29
    Edvardsen T. Can modern echocardiographic techniques predict drug induced cardiotoxicity? J Am Coll Cardiol 2011; 57: 2271-2272.